Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AllTranz is a specialty pharmaceutical company developing a unique set of dermal delivery products utilizing two proprietary technology platforms consisting of prodrug development and microneedle formulations. AllTranz will be a leader in the development of innovative drug design strategies delivered via unique dermal product solutions to treat neurological and a variety of other disorders. The broad range of offerings includes solutions for pain modulation, appetite stimulation, smoking cessation, substitution treatment for opiate addiction, as well as alcohol abuse, and abuse deterrent formulations for opiates. AllTranz will utilize its unique dermal drug delivery technology to develop its own products for broad market appeal, as well as partner with pharmaceutical companies seeking to leverage the AllTranz technology platform to improve delivery of existing drugs to form new chemical entities thereby extending patent franchises.

Agrify

Akanda Corp

Cronos Group

Greenlane Holdings

India Globalization Capital

Akerna Corp

Leafly Holdings

WM Technology

Chicago Atlantic Real Estate Finance

Village Farms International

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

Weed Stocks This Week: Major Earnings Blitz

Canaccord Genuity (TSX:CF, LSE:CF) analysts have reiterated a 'Buy' rating and issued an $11 price target for Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc in a note to clients.  The brokerage firm recently hosted Zynerba CEO Armando Anido and CFO Jim Fickenscher at its Canaccord Genuity (TSX:CF, LSE:CF) Growth Conference in Boston.

Zynerba Pharmaceuticals gets renewed 'Buy' rating, premium $11 price target from Canaccord Genuity after growth conference

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported financial results for the second quarter ended June 30, 2022, and provided an overview of its recent operational highlights and a pipeline update on its Zygel cannabidiol (CBD) skin gel.  "During the second quarter, we were pleased to announce positive topline results from our phase 2 trial of Zygel in patients with 22q,” said Armando Anido, chairman and chief executive officer of Zynerba in a statement.

Zynerba Pharmaceuticals reports Q2 results and provides operational update

Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023

Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights

DEVON, Pa., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present an overview and update of the Company at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022 at 9:00 a.m. ET at the InterContinental Boston in Boston, Mass.

Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it has entered into an equity purchase agreement for up to $20 million with Chicago-based institutional investor Lincoln Park Capital Fund LLC (LPC), in a move that will provide the company with financial flexibility in the clinical development of its Zygel CBD gel.  Under the terms of the deal, Zynerba will have the right, but not the obligation, to sell to LPC up to $20 million worth of shares of its common stock over the 36-month term of the agreement.

Zynerba Pharmaceuticals enters into equity purchase agreement for up to $20M with Lincoln Park Capital

DEVON, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced it has entered into an equity purchase agreement for up to $20 million with Lincoln Park Capital Fund, LLC (LPC), a Chicago-based institutional investor.

Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital

DEVON, Pa., July 07, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced two poster presentations at the 18th NFXF International Fragile X Conference, being held July 14-17, 2022, in San Diego, Calif. In addition, Zynerba management will present a company presentation during the conference's Keynote – Industry Updates session. Copies of the presentation and posters will be made available on the Zynerba corporate website following the presentations at www.zynerba.com/publications.

Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) announced positive top-line results from the Phase 2 INSPIRE trial of Zygel (Transdermal CBD gel) on pediatric behavioral and emotional symptoms of 22q11.2 deletion syndrome. The total score and all five subscales of the Anxiety, Depression.

Zynerba's Cannabidiol Formulated Gel Shows Encouraging Action In Genetic Disease

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced “very encouraging” data from a trial of its Zygel CBD gel for the treatment of 22q11.2 Deletion Syndrome (22q).  The exploratory, open-label Phase 2 INSPIRE trial was designed for signal detection by assessing the safety, tolerability and efficacy of Zygel (also known as ZYN002) for the treatment of behavioral symptoms of 22q in children and adolescents.

Zynerba Pharmaceuticals reports positive results from Phase 2 trial of Zygel CBD gel in 22q11.2 Deletion Syndrome

– The INSPIRE trial achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments –

Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome

China Pharma Holdings

Qutoutiao Inc - ADR

Check these three penny stocks out for your watchlist right now The post 3 Penny Stocks, Are They Worth Buying Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks, Are They Worth Buying Right Now?

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it will deliver oral and poster presentations on its CBD gel Zygel at the American Society of Clinical Psychopharmacology Annual Meeting (ASCP 2022), held this week in Scottsdale, Arizona.  The oral presentation will focus on the demonstrated long-term safety and potential effectiveness of Zygel in children and adolescents with Fragile X syndrome, and the poster presentation will highlight design enhancements incorporated into its RECONNECT trial, the company said.

Zynerba Pharmaceuticals presents data on Zygel CBD gel at American Society of Clinical Psychopharmacology event this week

– Poster presentation highlights design enhancements incorporated into pivotal RECONNECT trial –

Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has reported results for the first quarter that reveal ample cash on hand, giving the company scope to run pivotal trials of its flagship product Zygel (ZYN002). As of March 31, 2022, the Devon, Pennsylvania-based company increased its cash and equivalents to $69.7 million, compared to $67.8 million at the end of December 2021.

Zynerba ends 1Q with strong $69.7M cash runway to advance its novel Zygel CBD Gel for Fragile X Syndrome

– Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 –

Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc, a leader in transdermal cannabinoid therapies for rare neuropsychiatric disorders, revealed that it is making an oral podium presentation at the International Society for Autism Research's four-day annual meeting starting on May 11, 2022. The meeting is being held both in-person and virtually from Austin, Texas.

Zynerba presents positive data on Zygel in children and adolescents with Fragile X Syndrome at International Society for Autism Research meeting

– Data support the long-term safety and effectiveness of Zygel –

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meeting

DEVON, Pa., May 09, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced an oral podium presentation at the International Society for Autism Research Annual Meeting (INSAR 2022), being held both in-person and virtually May 11-14, 2022, from Austin, TX. A copy of the presentation will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc said it presented a poster on the long-term safety and efficacy of its cannabidiol transdermal gel, Zygel, at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting held in New Orleans, Louisiana, and virtually, from April 28-30, 2022. The poster, titled 'Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome (FXS) (ZYN2-CL-017)', showed Zygel was well-tolerated in long-term administration of up to 38 months of exposure in an ongoing safety and efficacy study of the drug in children and adolescents with FXS.

Zynerba Pharmaceuticals announces presentation of poster on Zygel at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, presented a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, held April 28-30, 2022, in New Orleans, La., and virtually. A copy of the poster is available on the Zynerba corporate website at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., April 21, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2022 Society of Biological Psychiatry (SOBP) Annual Meeting, being held April 28-30, 2022, in New Orleans, La., and virtually. A copy of the poster will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting

DEVON, Pa., April 05, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022, at 12:45 p.m. ET.

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

DEVON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Stephen O'Quinn, Vice President, Medical Affairs, Zynerba Pharmaceuticals, will participate in a panel discussion at the 2022 Cantor Rare Orphan Disease Summit taking place virtually March 29-30, 2022.

Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit

Zynerba (ZYNE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

News for Zynerba Pharmaceuticals Stock (ZYNE)